| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Insider buying and selling activity across 114 companies in the Pharmaceuticals industry. Part of the Health Care sector.
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| May 18, 2017 | ALKS Alkermes Plc. | Landine Michael J | SVP, Corp Dev., Alkermes, Inc. | Sell | 10,000 | $57.23 | $572,254.33 | -3.0% | |
| May 18, 2017 | NBIX Neurocrine Biosciences Inc | Obrien Christopher Flint | Chief Medical Officer | Sell | 105,634 | $53.32 | $5,632,404.88 | -68.3% | |
| May 18, 2017 | NVS Novartis AG | Novartis Bioventures Ltd | 10% Owner | Sell | 9,019 | $25.50 | $229,963.76 | -0.4% | |
| May 18, 2017 | NBIX Neurocrine Biosciences Inc | Lippoldt Darin60 | Chief Legal Officer | Sell | 10,000 | $53.27 | $532,700.00 | -43.2% | |
| May 17, 2017 | ALKS Alkermes Plc. | Pops Richard F57 | Director And CEO, Alkermes Plc | Sell | 50,000 | $58.19 | $2,909,439.37 | -2.5% | |
| May 17, 2017 | NVS Novartis AG | Novartis Bioventures Ltd | 10% Owner | Sell | 42,615 | $25.90 | $1,103,625.63 | -0.9% | |
| May 16, 2017 | EGRX Eagle Pharmaceuticals, Inc. | Pernock David | Pres. &Chief Comm. Officer | Buy | 200 | $82.24 | $16,448.00 | +39.1% | |
| May 15, 2017 | PCRX Pacira Biosciences, Inc. | Williams Kristen Marie76 | CAO And General Counsel | Sell | 21,041 | $50.86 | $1,070,145.26 | -57.3% | |
| May 15, 2017 | PCRX Pacira Biosciences, Inc. | Scibetta James S | President | Sell | 20,000 | $51.20 | $1,024,000.00 | -42.5% | |
| May 15, 2017 | IRWD Ironwood Pharmaceuticals Inc | McCourt Thomas A66 | Chief Commercial Officer | Sell | 30,000 | $18.20 | $546,000.00 | -100% | |
| May 12, 2017 | COLL Collegium Pharmaceutical, Inc | Brannelly Paul | Executive Vice President &CFO | Buy | 10,000 | $9.18 | $91,800.00 | +10.0% | |
| May 12, 2017 | SCYX Scynexis Inc | Taglietti Marco | Chief Executive Officer | Buy | 25,000 | $1.69 | $42,250.00 | +9.9% | |
| May 12, 2017 | LNTH Lantheus Holdings, Inc. | Schaffer Derace L | Director | Sell | 5,000 | $16.55 | $82,750.00 | -7.8% | |
| May 12, 2017 | MRK Merck & Co., Inc. | Kidder C Robert | Director | Sell | 5,000 | $63.54 | $317,695.00 | -34.9% | |
| May 12, 2017 | SCYX Scynexis Inc | Angulo Gonzalez David | Chief Medical Officer | Buy | 15,000 | $1.70 | $25,500.00 | +31.9% | |
| May 12, 2017 | PAHC Phibro Animal Health Corp | Carlson Gerald K | Director | Sell | 8,662 | $33.51 | $290,263.62 | -100% | |
| May 11, 2017 | PAHC Phibro Animal Health Corp | Warras Dean J | Pres Animal Health &Nutr N.a. | Sell | 10,000 | $33.54 | $335,400.00 | -100% | |
| May 11, 2017 | AMPH Amphastar Pharmaceuticals, Inc. | Prins Richard K61 | Director | Sell | 7,500 | $15.43 | $115,725.00 | -24.6% | |
| May 11, 2017 | ALKS Alkermes Plc. | Landine Michael J | SVP, Corp Dev., Alkermes, Inc. | Sell | 10,000 | $57.01 | $570,082.00 | -5.8% | |
| May 11, 2017 | BHC Bausch Health Companies Inc. | De Schutter Richard U | Director | Buy | 20,000 | $13.90 | $278,000.00 | +39.5% | |
| May 11, 2017 | PAHC Phibro Animal Health Corp | Carlson Gerald K | Director | Sell | 63,338 | $33.31 | $2,109,687.88 | -100% | |
| May 10, 2017 | PAHC Phibro Animal Health Corp | Bfi Co., LLC | 10% Owner | Sell | 1,400 | $34.04 | $47,656.00 | -1.9% | |
| May 10, 2017 | PAHC Phibro Animal Health Corp | Bendheim Jack52 | President And CEO | Sell | 1,400 | $34.04 | $47,656.00 | -1.9% | |
| May 10, 2017 | LNTH Lantheus Holdings, Inc. | Schaffer Derace L | Director | Sell | 10,000 | $15.75 | $157,500.00 | -13.6% | |
| May 10, 2017 | ALKS Alkermes Plc. | Pops Richard F57 | Director And CEO, Alkermes Plc | Sell | 25,000 | $57.29 | $1,432,243.73 | -1.9% |
The blue line has two modes, toggled with the Relative and Absolute buttons:
Relative (default) shows cumulative industry performance with both the overall market and parent sector movements removed. When the line rises above 100, the industry is outperforming its sector; below 100 means underperforming. This is calculated using factor returns via weighted least squares (WLS) regression, isolating pure industry-specific behavior.
Absolute shows the total cumulative return of the industry including market and sector movement. This reflects what an investor actually experienced — an industry can show strong absolute gains even while underperforming its sector in relative terms.
Both views start at an index of 100. Other return drivers such as momentum, value, or size are deliberately retained in both modes, since these are part of what makes an industry behave the way it does and may reflect the conditions insiders are responding to.